TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05350163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
Study: NCT05159999

Intervention type: OTHER
Group type: OTHER
Intervention: Dry weight target adjustment
Description: Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry weight target adjustment
Description: Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry weight target adjustment
Description: Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-hypertensive medications
Description: Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive medications
Description: Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive medications
Description: Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
Study: NCT04276233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
Study: NCT04733053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Description: The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
Study: NCT05268510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapOX
Description: Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
Study: NCT06577987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CID-078 Monotherapy
Description: Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
Study: NCT05152108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI feasibility test
Description: Testing the feasibility of BCI device by determining the accuracy of BCI control
Study: NCT05947864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological samples (blood and oral fluid)
Description: For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological samples (blood and oral fluid)
Description: For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)
Study: NCT06090565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Two 400 mg tablets will be administered orally to equal a 800 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: One 100 mg tablet will be administered orally twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxon
Description: Dose of 1 g intramuscular one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Four 500 mg tablets will be administered orally to equal a 2 g dose.
Study: NCT05150015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)
Description: Single arm study
Study: NCT05702138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
Study: NCT05505344

Intervention type: DEVICE
Intervention: VentriJect Seismofit validation
Description: All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
Study: NCT06456255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensorcaine with Epinephrine
Description: The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Punctures without any medication injected onto the septum
Study: NCT05946603

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Administration of IS-002
Description: Intravenous administration of IS-002 approximately 24 hours prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of IS-002
Description: Intravenous administration of IS-002 approximately 24 hours prior to surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firefly fluorescent imaging
Description: Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
Description: Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
Description: Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
Study: NCT06022796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Ketogenic Ready-to-Eat Meals
Description: Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Ketogenic Diet
Description: Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
Study: NCT06227897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib 110 mg per day orally for 3 years.
Study: NCT04787107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Chair Massage
Description: Healthcare staff will be placed into either massage or break intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Chair Massage
Description: Healthcare staff will be placed into either massage or break intervention
Study: NCT06322888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Program
Description: A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
Study: NCT05567250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Telephone-based ACEs care coordination
Description: The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
Study: NCT06312202

Intervention type: OTHER
Intervention: Drowning
Description: Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.

Intervention type: OTHER
Intervention: Drowning
Description: Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
Study: NCT06415461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PremierMaxCB®-Platinum (CFL001);
Description: Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PremierMaxCB®-Platinum (CFL001);
Description: Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PremierMaxCB®-Platinum (CFL001);
Description: Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood
Study: NCT05210491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review of eyelid positioning in increasing brightness levels
Description: Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
Study: NCT06256484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATA3219
Description: ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
Study: NCT06038669

Intervention type: DEVICE
Intervention: Dried blood spot device
Description: Patients will be asked to provide a dried blood spot sample

Intervention type: OTHER
Intervention: Healthcare professional interviews
Description: Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
Study: NCT04448977

Intervention type: DRUG
Intervention: Ocrevus
Description: Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education.
Study: NCT05287646

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Suspension First
Description: Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevated Vacuum Suspension First
Description: Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
Study: NCT06367348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mlambe
Description: A combined economic and relationship-strengthening intervention. Sessions consist of incentivized savings accounts, financial literacy training, and relationships skills building, including couple communication.
Study: NCT06121271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 DOTATATE (Lutathera®)
Description: Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
Study: NCT06617546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-101
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lyophilized powder for subcutaneous or intravenous injection
Study: NCT06538870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implants
Description: Dental implants will be placed in the edentulous area as per standard surgical procedure and as appropriate to bring the patient to standard of care restoratively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implants
Description: Dental implants will be placed in the edentulous area as per standard surgical procedure and as appropriate to bring the patient to standard of care restoratively.
Study: NCT06612645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7H3-IL7Ra CAR-T cells
Description: Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
Study: NCT05490680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg
Description: Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Film